Safety of direct oral anticoagulants in patients with liver disease: a systematic review and meta-analysis.

IF 1.6 4区 医学 Q2 Medicine Acta Clinica Belgica Pub Date : 2023-06-01 DOI:10.1080/17843286.2022.2108259
Yan Zhao, Liyao Zhu, Yang Yang, Han Gao, Rui Zhang
{"title":"Safety of direct oral anticoagulants in patients with liver disease: a systematic review and meta-analysis.","authors":"Yan Zhao,&nbsp;Liyao Zhu,&nbsp;Yang Yang,&nbsp;Han Gao,&nbsp;Rui Zhang","doi":"10.1080/17843286.2022.2108259","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Direct oral anticoagulants (DOACs), such as apixaban, edoxaban, rivaroxaban, or dabigatran, are an effective treatment for atrial fibrillation (AF) and deep venous thromboembolism. We hope to evaluate the safety of DOACs versus warfarin/low molecular weight heparin (LMWH) in improving bleeding events in patients with different severity of the liver disease.</p><p><strong>Methods: </strong>We systematically searched the Cochrane Library, PubMed, and Embase databases for studies reporting the effects of DOACs in patients with liver cirrhosis. A random-effects model or fixed-effects model was selected to pool risk ratios (RR) and 95% confidence intervals (CI).</p><p><strong>Results: </strong>A total of 18 studies involving 41,447 participants was included in this meta-analysis. Compare with warfarin/ LMWH, the use of DOACs significantly reduced the incidence of all bleeding (RR: 0.76; 95%CI: 0.66 to 0.87), major bleeding (RR: 0.51; 95%CI: 0.28 to 0.91), intracranial hemorrhage (RR: 0.50; 95%CI: 0.31 to 0.81), and gastrointestinal bleeding (RR: 0.76, 95% CI: 0.60 to 0.97), and all-cause death in patients with liver disease (RR: 0.77; 95%CI: 0.62 to 0.95). Similar results were observed in atrial fibrillation patients with liver disease and cirrhosis subgroups. Furthermore, the pooled estimates of the Child-Turcotte-Pugh (CTP) class indicated that DOACs reduced the incidence of all bleeding (RR: 0.61; 95%CI: 0.45 to 0.82), gastrointestinal bleeding (RR 0.55; 95%CI: 0.37 to 0.83), and all-cause death (RR: 0.62; 95%CI: 0.49 to 0.79) in patients with mild to moderate cirrhosis.</p><p><strong>Conclusions: </strong>Our study demonstrates that DOACs significantly reduce the risk of bleeding in patients with liver disease compared with warfarin/LMWH.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":"78 3","pages":"234-244"},"PeriodicalIF":1.6000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Clinica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17843286.2022.2108259","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Direct oral anticoagulants (DOACs), such as apixaban, edoxaban, rivaroxaban, or dabigatran, are an effective treatment for atrial fibrillation (AF) and deep venous thromboembolism. We hope to evaluate the safety of DOACs versus warfarin/low molecular weight heparin (LMWH) in improving bleeding events in patients with different severity of the liver disease.

Methods: We systematically searched the Cochrane Library, PubMed, and Embase databases for studies reporting the effects of DOACs in patients with liver cirrhosis. A random-effects model or fixed-effects model was selected to pool risk ratios (RR) and 95% confidence intervals (CI).

Results: A total of 18 studies involving 41,447 participants was included in this meta-analysis. Compare with warfarin/ LMWH, the use of DOACs significantly reduced the incidence of all bleeding (RR: 0.76; 95%CI: 0.66 to 0.87), major bleeding (RR: 0.51; 95%CI: 0.28 to 0.91), intracranial hemorrhage (RR: 0.50; 95%CI: 0.31 to 0.81), and gastrointestinal bleeding (RR: 0.76, 95% CI: 0.60 to 0.97), and all-cause death in patients with liver disease (RR: 0.77; 95%CI: 0.62 to 0.95). Similar results were observed in atrial fibrillation patients with liver disease and cirrhosis subgroups. Furthermore, the pooled estimates of the Child-Turcotte-Pugh (CTP) class indicated that DOACs reduced the incidence of all bleeding (RR: 0.61; 95%CI: 0.45 to 0.82), gastrointestinal bleeding (RR 0.55; 95%CI: 0.37 to 0.83), and all-cause death (RR: 0.62; 95%CI: 0.49 to 0.79) in patients with mild to moderate cirrhosis.

Conclusions: Our study demonstrates that DOACs significantly reduce the risk of bleeding in patients with liver disease compared with warfarin/LMWH.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肝病患者直接口服抗凝剂的安全性:一项系统综述和荟萃分析
背景:直接口服抗凝剂(DOACs),如阿哌沙班、依多沙班、利伐沙班或达比加群,是房颤(AF)和深静脉血栓栓塞的有效治疗方法。我们希望评估DOACs与华法林/低分子肝素(LMWH)在改善不同严重程度肝病患者出血事件方面的安全性。方法:我们系统地检索了Cochrane图书馆、PubMed和Embase数据库,以报告DOACs对肝硬化患者的影响。选择随机效应模型或固定效应模型汇总风险比(RR)和95%置信区间(CI)。结果:本荟萃分析共纳入18项研究,涉及41,447名参与者。与华法林/低分子肝素相比,DOACs的使用显著降低了所有出血的发生率(RR: 0.76;95%CI: 0.66 ~ 0.87)、大出血(RR: 0.51;95%CI: 0.28 ~ 0.91)、颅内出血(RR: 0.50;95%CI: 0.31 ~ 0.81),胃肠道出血(RR: 0.76, 95%CI: 0.60 ~ 0.97),以及肝病患者的全因死亡(RR: 0.77;95%CI: 0.62 ~ 0.95)。在伴有肝病和肝硬化的房颤患者亚组中也观察到类似的结果。此外,child - turcote - pugh (CTP)分类的汇总估计表明,DOACs降低了所有出血的发生率(RR: 0.61;95%CI: 0.45 ~ 0.82),胃肠道出血(RR 0.55;95%CI: 0.37 ~ 0.83)和全因死亡(RR: 0.62;95%CI: 0.49 ~ 0.79)。结论:我们的研究表明,与华法林/低分子肝素相比,DOACs可显著降低肝病患者出血的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Acta Clinica Belgica
Acta Clinica Belgica 医学-医学:内科
CiteScore
2.90
自引率
0.00%
发文量
44
审稿时长
6-12 weeks
期刊介绍: Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine primarily publishes papers on clinical medicine, clinical chemistry, pathology and molecular biology, provided they describe results which contribute to our understanding of clinical problems or describe new methods applicable to clinical investigation. Readership includes physicians, pathologists, pharmacists and physicians working in non-academic and academic hospitals, practicing internal medicine and its subspecialties.
期刊最新文献
Flemish consensus statement on the prevention, diagnosis and treatment of urinary tract infections in older nursing home residents. Validation of EUCAST rapid antimicrobial susceptibility testing directly from positive blood cultures in a non-automated lab setting. A multimodal treatment of basilar artery re-occlusion - case report. 'Iatrogenic septic pit': empyema, a rare complication after endobronchial valve placement. The first reported familial case of statin-induced immune-mediated necrotizing myopathy associated with anti-hydroxy-3-methylglutaryl-CoA reductase autoantibodies and HLA DRB1*11:01
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1